# Anticoagulation-related complications and their outcomes in hemodialysis patients with acute kidney injury at selected hospitals in Ethiopia.

Kedir (hanan.muzeyin@aau.edu.et)<sup>1\*</sup>, Abdella Yabeyu 4 Hanan Muzeyin Birhan (birhanabdella@gmail.com)<sup>2</sup>, Addisu Melkie Ejigu (addisumelkieejigu@gmail.com)<sup>3</sup>, Tamrat 5 6 Assefa Tadesse (tamrat.assefa@aau.edu.et)<sup>1</sup>. Eskinder Avalew Sisav 7 (eskinder.ayalew@aau.edu.et)<sup>1</sup>

- <sup>8</sup> <sup>1</sup>Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Collage of Health
- 9 Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
- <sup>2</sup>Department of Pharmacy, College of Medicine and Health Sciences, Ambo University, Ambo,
  Ethiopia.
- 12 <sup>3</sup>Department of Internal Medicine, Addis Ababa University, Addis Ababa, Ethiopia
- 13 \*Correspondence Author
- 14 Hanan Muzeyin Kedir
- 15 hanan.muzeyin@aau.edu.et
- 16 Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Collage of Health
- 17 Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
- 18 Telephone: +251912275828
- 19 These authors contributed equally to this work.
- 20 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 21 Abstract

Introduction: During hemodialysis (HD), the presence of clots in the dialyzer can diminish the effective surface area of the device. In severe cases, clot formation in the circuit can halt treatment and lead to blood loss in the system. Thus, ensuring proper anticoagulation during HD is crucial to prevent clotting in the circuit while safeguarding the patient from bleeding risks. This study aimed to evaluate anticoagulation outcomes and related factors in HD patients with acute kidney injury (AKI) at selected hospitals in Ethiopia.

Method: A prospective, multicenter observational study was carried out between October 1, 2021, and March 31, 2022. The study encompassed all AKI patients undergoing HD at least 30 once during the study period. Descriptive statistics were utilized to summarize the data, and 31 multinomial logistic regression analysis was employed to identify factors associated to clotting 32 and bleeding.

**Results**: Data were gathered from 1010 HD procedures conducted on 175 patients. Extracorporeal circuit clotting was detected in 34 patients during 39 (3.9%) dialysis sessions, while bleeding incidents occurred in 27 patients across 29 (2.9%) sessions. A statistically significant association was found between both the total number of HD treatments and blood flow rate with incidents of clotting. Factors such as length of hospitalization, serum creatinine levels at admission, signs and symptoms associated with uremia, along with utilization of anticoagulants or antiplatelet medications demonstrated an association with bleeding events.

40 **Conclusion**: Clotting affected 19.4% of participants, while bleeding occurred in 15.4%,

41 underscoring the importance of close monitoring. The frequency of HD sessions and blood

42 flow rate are correlated with clotting, while hospitalization duration, serum creatinine levels,

43 uremic symptoms, and anticoagulant use are associated with bleeding events.

#### 44 Keywords: Acute kidney injury, Anticoagulation, Hemodialysis, Ethiopia

45

## 46 Introduction

Hemodialysis (HD) constitutes a medical procedure that facilitates the removal of waste 47 products from the bloodstream externally via a device outfitted with specialized filtration 48 49 systems. The predominant cause for arteriovenous access failure is attributed to thrombosis, representing 80%-85% of cases (1,2). Within the HD protocol, components such as the dialyzer 50 51 and other elements of the extracorporeal blood circuit are also vulnerable to thrombotic events. This includes tubing, arterial and venous bubble traps in addition to needles or catheters utilized 52 for vascular access—all factors contributing to coagulation phenomena (3.4). Notably, arterial 53 and venous bubble traps exhibit a heightened susceptibility towards clotting owing to 54 diminished blood flow rates leading potentially to stasis and hence clot formation. Such 55 premature cessation of HD sessions precipitates inadequate dialysis alongside possible 56 hematologic losses. Furthermore clots within this circuitry can herald significant negative 57 repercussions including reduction in solute clearance during therapy amplified costs, and 58 increased operational burden (5-7). 59

Maintaining an optimal balance between insufficient and excessive heparinization is essential for achieving proper anticoagulation during HD in order to avert bleeding and clot formation within the extracorporeal circuit, respectively (6, 8). It is imperative to administer the minimal efficacious dose of anticoagulant to ensure that the dialyzer and venous chamber remain clear of blood cell fragments while also facilitating rapid hemostasis at the vascular access site following treatment (5). Although anticoagulant dosing varies among individuals due to patientspecific factors and HD-related variables, it is generally lower than doses required for full

anticoagulation. Inadequate levels of anticoagulation may reduce dialysis's effectiveness ineliminating waste products from the bloodstream (4-6).

Unfractionated heparin (UFH) is extensively utilized as an anticoagulant during HD owing to 69 its long-standing history in clinical practice and a desirable safety profile characterized by a 70 brief half-life (8,9). The European guidelines for optimal HD practices suggest an initial bolus 71 of 50 IU/kg UFH administered via the arterial access needle, followed by a continuous infusion 72 73 maintenance dosage ranging from 500 to 1500 IU of UFH per hour. It's recommended that the use of UFH be minimized, especially since patients with acute kidney injury AKI often have 74 compromised health and may require daily dialysis treatments. In instances of clotting or 75 bleeding, modifications in dosage or the implementation of heparin-free dialysis methods might 76 become necessary. Although alternative anticoagulation techniques targeting the extracorporeal 77 circuit exist, their adoption has been limited due to their complex nature and higher requisites 78 79 for administration time and workforce involvement for monitoring purposes (10-12).

Critically ill patients often display impaired coagulation and low platelet counts, which 80 significantly increases their risk of bleeding when systemic anticoagulants are used. As such, it 81 is advised that these individuals avoid any treatments that further heighten this risk, especially 82 those involving systemic anticoagulants (6,13). In situations where the risk of bleeding is a 83 concern, the European Best Practice Guidelines recommend alternatives like regular saline 84 flushing or local citrate anticoagulation during HD, avoiding systemic anticoagents entirely. 85 This approach not only facilitates quick adjustments to treatment but also enables easy 86 monitoring for clotting within the dialyzer and may help in preventing clots from forming 87 initially (2,10). The goal of this study is to explore outcomes related to anticoagulation therapy 88 and factors influencing its outcome among AKI patients receiving HD at Tikur Anbessa 89

90 Specialized Hospital (TASH) and St. Paul's Hospital Millennium Medical College (SPHMMC)
91 in Addis Ababa, Ethiopia.

## 92 Material and Methods

### 93 Study Setting

The study took place in the dialysis departments of TASH and SPHMMC, located in Addis
Ababa, Ethiopia. TASH introduced HD services back in 1980 and presently caters to acute
dialysis needs. Meanwhile, SPHMMC began its provision of acute dialysis services in August
2013 before extending these services to include maintenance dialysis for kidney transplantation
starting from early 2015 (14).

Despite the lack of a specific written protocol for HD patients, anticoagulation was frequently 99 administered at both hospitals. UFH was used during HD, but the prescribed doses of heparin 100 varied slightly between the two centers. At TASH, UFH was administered in one of three ways: 101 (i) the standard dose, 1 ml (5000 IU) of UFH, was diluted with 4 ml of normal saline (total of 102 5 ml). This was followed by a 2 ml initial bolus and a continuous infusion of 1 ml/hr; (ii) the 103 minimal or half dose of 0.5 ml (2500 IU) of UFH was diluted with 4.5 ml of normal saline 104 (total of 5 ml). This was followed by a 2 ml initial bolus and a continuous infusion of 1 ml/hr; 105 (iii) heparin-free saline flushes of 30 to 50 ml were given every 30 minutes. At SPHMMC, 1 106 ml of UFH was diluted with 3 ml of normal saline (total of 4 ml) and administered as a bolus 107 of 1 ml, followed by a continuous infusion of 1 ml/hr. 108

## 109 Study Design and Period

110 A comprehensive, multicenter observational study was carried out over a duration of six months,

- starting from October 1st, 2021 and concluding on March 31st, 2022. This study took place at
- two major hospitals (TASH and SPHMMC) in Addis Ababa, Ethiopia.

### **113 Sampling and Sample Size Determination**

On average, the dialysis clinics at TASH and SPHMMC serve approximately 15 and 30 AKI patients per month, respectively. All patients meeting the eligibility criteria were considered for inclusion in the study. Consequently, a total of 175 patients identified during the study period, meeting the established criteria, participated in this research. Specifically, 122 of these patients received treatment at SPHMMC, while the remaining 53 were from TASH.

#### 119 Inclusion and Exclusion Criteria

All patients suffering from AKI, aged 12 years and older, who underwent HD at least once during the designated study period were eligible for inclusion in this study. Nonetheless, individuals diagnosed with chronic kidney disease who were undergoing regular maintenance dialysis treatments, as well as those who expressed a refusal to participate in the study, were systematically excluded from consideration.

#### 125 Data Collection Instruments and Techniques

126 The data collection questionnaire, consisting of four sections, was developed through a 127 thorough review of relevant literature related to the study's objectives. The aim was to collect 128 demographic characteristics and clinical variables of patients to assess outcomes related to

anticoagulation. Pre-testing was carried out, and all necessary adjustments to the data collection
tool were implemented(4,6,9,15–18).

The initial section of the data collection tool was designed to gather information regarding the 131 sociodemographic characteristics of the patients. Subsequently, the second section assessed the 132 clinical features of the patients, including inquiries about the cause of AKI, indications for HD, 133 concomitant medical conditions, co-administered medications, and current use of 134 anticoagulants and/or antiplatelet drugs. The third part of the data collection tool focused on 135 recording essential laboratory results upon admission and discharge. Finally, the fourth section 136 specifically documents the comprehensive details of each HD session. Patients were closely 137 monitored during each session, with data collectors prospectively recording various parameters 138 related to HD, such as venous pressure, ultrafiltration volume, blood flow, dialysate flow, and 139 approach to UFH usage during HD. Additionally, incidents of clotting or bleeding were 140 documented, along with the interventions implemented to manage these occurrences. 141

#### 142 Data Quality Assurance

To ensure data quality, the principal investigator closely monitored each activity to ensure comprehensive data collection. Unclear terms were promptly clarified, and the necessary corrections were made during the pre-test phase before commencing the main study. Data collection was performed using three BSc. nurses and a pharmacist who were recruited as data collectors. They underwent training to establish a consistent understanding and interpretation of the instrument, including a briefing on the study's objectives and commitment to maintaining core ethical principles throughout the data collection period.

#### 150 Data Analysis

Data completeness was verified before entering the statistical package for social science (SPSS) version 26 for a thorough analysis. Descriptive statistics, including the mean, median, percentage, and standard deviation (SD), were then used to succinctly summarize the data. Multinomial logistic regression was used to identify predictive factors for anticoagulationrelated outcomes in patients with AKI undergoing HD. A P-value < 0.05 was considered the threshold for declaring statistically significant associations.

## 157 Ethical Considerations

Ethical clearance was secured from Addis Ababa University, School of Pharmacy, the Ethical Review Committee (reference number ERB/SOP/257/13/2021), and the Institutional Review Board of SPHMMC (reference number PM25/386). Study participants provided both written and verbal consent before participating, and their confidentiality was maintained by avoiding the recording of identifying information such as patient names. The collected data remained securely stored throughout the study and was appropriately destroyed upon study completion.

#### **164 Operational Definition**

Anticoagulation-related complication: were defined as the occurrence of any circuit clotting or bleeding during HD, whether with the use of UFH as an anticoagulant for dialysis or in a heparin-free approach.

## 168 **Results**

## **169** Socio-demographic Characteristics of Study Participants

- 170 Of the 175 patients included in the study, an almost equal number were males (50.9%) and
- females (49.1%), with a mean age of  $40 \pm 17.8$  years involved and four female were pregnant.
- Among the 175 patients, 66.9% were paid out-of-pocket for dialysis and 2.3% were involved
- in smoking, drinking alcohol, and chewing khat (Table 1).

| Variable                   | Category                 | n (%)      |
|----------------------------|--------------------------|------------|
|                            |                          |            |
| Age (years), mean $\pm$ SD |                          | 40±17.8    |
| Sex                        | Male                     | 89 (50.9)  |
|                            | Female                   | 86 (49.1)  |
| Marital status             | Single                   | 55 (31.4)  |
|                            | Married                  | 103 (58.9) |
|                            | Widowed                  | 10 (5.7)   |
|                            | Divorced                 | 7 (4)      |
| Pregnancy                  | Pregnant                 | 4 (4.7)    |
|                            | Not pregnant             | 71 (82.5)  |
|                            | Postpartum               | 11 (12.8)  |
| Education                  | Unable to read and write | 23 (13.1)  |
|                            | Primary education        | 42 (24)    |
|                            | Secondary education      | 63 (36)    |
|                            |                          |            |

#### 174 Table 1: Socio-demographic characteristics of AKI patients who undergo HD (n=175)

| It is made available under a CC-B | Y 4.0 International license . |
|-----------------------------------|-------------------------------|

|                   | Diploma and above        | 47 (26.9)  |
|-------------------|--------------------------|------------|
| Weight (Kg)       |                          | 61±13.9    |
| Method of payment | Insurance                | 58 (33.1)  |
|                   | Out of pocket            | 117 (66.9) |
| Substance use     | Smoking                  | 7 (4)      |
|                   | Chewing Khat             | 9 (5.1)    |
|                   | Alcohol                  | 26 (14.9)  |
|                   | Smoking + Khat + Alcohol | 4 (2.3)    |
|                   |                          |            |

175

#### **176** Clinical Characteristics

The average length of hospital stay was 14.2 days, range, 2–40 days. The three most common 177 causes of AKI were acute tubular necrosis (29%), nephrotic syndrome (24%), and sepsis 178 (22.9%). Pregnancy-related causes also included preeclampsia/eclampsia (5.1%) and HELLP 179 syndrome (4.6%). The major indications for dialysis were uremic signs and symptoms (70.3%), 180 181 followed by fluid overload (50.3%). Common underlying comorbidities identified were hypertension (55.4%) and anaemia (49.7%), and 13.1% of AKI cases were superimposed on 182 chronic kidney disease. UFH 7500 IU twice per day (48%) was the most widely used 183 184 anticoagulant regimen in the study population, followed by 5000 IU twice a day (14.3%) to prevent deep venous thrombosis (Table 2). 185

#### 186 Table 2: Clinical characteristics of AKI patients who undergo HD (n=175)

| Variables | Category | n (%) |
|-----------|----------|-------|
|           |          | Yes   |

| Length of hospitalization (days), mean $\pm$ |                           | $14.2\pm9.9$ |
|--|---------------------------|--------------|
| SD   |                           |              |
| Cause of AKI                                 | Acute tubular necrosis    | 49 (28)      |
|  | Nephritic syndrome        | 42 (24)      |
|  | Sepsis                    | 40 (22.9)    |
|  | Severe dehydration        | 17 (9.7)     |
|  | Interstitial nephritis    | 25 (14.3)    |
|  | Shock                     | 19 (10.9)    |
|  | Poison                    | 17 (9.7)     |
|  | Urinary tract obstruction | 11 (6.3)     |
|  | Nephrotoxic drugs         | 8 (4.6)      |
|  | Rhabdomyolysis            | 3 (1.7)      |
|  | HELLP syndrome            | 8 (4.6)      |
|  | Post-kidney transplant    | 6 (2 1)      |
|  | rejection                 | 6 (3.4)      |
|  | Lupus nephritis           | 9 (5.1)      |
|  | Preeclampsia/Eclampsia    | 9 (5.1)      |
|  | Acute Glomerulonephritis  | 7 (4)        |
|  | Hemorrhage                | 5 (2.9)      |
|  | Others*                   | 4 (2.3)      |
|  |                           | 102 (70.2)   |
| Dialysis indication                          | Uremic signs and symptoms | 123 (70.3)   |
|  | Fluid overload            | 88 (50.3)    |
|  | Hyperkalemia              | 79 (45.1)    |
|  | Metabolic Acidosis        | 66 (37.7)    |

| Comorbidity                     | Atrial fibrillation         | 1 (0.6)    |
|---------------------------------|-----------------------------|------------|
|                                 | Coronary arterial disease   | 1 (0.6)    |
|                                 | Stroke                      | 6 (3.4)    |
|                                 | Hypertension                | 97 (55.4)  |
|                                 | Congestive heart disease    | 22 (12.6)  |
|                                 | Gastrointestinal ulceration | 29 (16.6)  |
|                                 | Chronic Kidney Disease      | 23 (13.1)  |
|                                 | Anemia                      | 87 (49.7)  |
|                                 | Deep vein thrombosis        | 5 (2.9)    |
|                                 | Pulmonary embolism          | 3 (1.7)    |
|                                 | Type 2 Diabetes             | 22 (12.6)  |
|                                 | HIV                         | 11 (6.3)   |
|                                 | Pulmonary tuberculosis      | 9 (5.1)    |
|                                 | Hepatitis B virus           | 5 (2.9)    |
|                                 | Others**                    | 41 (23.4)  |
| Concurrent anticoagulant and/or |                             | 124 (70.9) |
| antiplatelet                    |                             | 124 (70.9) |
|                                 | UFH 2500 IU SC BID          | 1 (0.6)    |
|                                 | UFH 5000IU SC Bid           | 25 (14.3)  |
|                                 | UFH 7500IU SC Bid           | 84 (48)    |
|                                 | UFH 17500IU SC Bid          | 5 (2.9)    |
|                                 | Warfarin 5mg PO Daily       | 8 (4.6)    |
|                                 | ASA 81mg PO Daily           | 20 (11.4)  |
|                                 | Enoxaparin 40mg SC Bid      | 3 (1.7)    |
|                                 | Clopidogrel 75mg PO Daily   | 2 (1.1)    |
|                                 |                             |            |

Concomitant drugs use

166 (94.9)

- 187 \* (malaria, kidney trauma, cardio-renal syndrome, acute fatty liver of pregnancy)
- 188 \*\* (prostate cancer, BPH, epilepsy, leukemia, gout arthritis, cerebral malaria)

### **Laboratory Findings**

- 190 Upon admission and upon discharge, it was noted that there were low hemoglobin levels present.
- 191 Furthermore, the mean serum creatinine level recorded at the time of admission stood at  $8.3 \pm$
- 192 3.4 mg/dl, which experienced a significant decrease by 3 mg/dl by the time of discharge. Table
- 193 3 in our document provides a summarized outline showing these changes among other selected
- 194 laboratory parameter values observed during this period.

| Variables                            | Mean ± SD         |                 |
|--------------------------------------|-------------------|-----------------|
|                                      | Admission         | Discharge       |
| Hemoglobin (g/dl)                    | $10.3 \pm 7.6$    | $10.3 \pm 6.4$  |
| WBC count (10 <sup>3</sup> /ml)      | $11.1 \pm 5.6$    | $9.8\pm4.9$     |
| Platelet count (10 <sup>3</sup> /ml) | $235.9 \pm 140.1$ | $268.3 \pm 131$ |
| Serum creatinine (mg/dl)             | 8.3 ± 3.4         | $5.3 \pm 3.1$   |
| Urea (mg/dl)                         | $137.5 \pm 80.3$  | 82.1 ± 63.4     |
| Serum potassium (mEq/L)              | $5.3 \pm 1.1$     | $4.4 \pm 0.8$   |

#### 195 Table 3: Selected Laboratory Values of AKI patients who undergo HD (n=175)

196

#### 197 Characteristics of HD Sessions

From October 2021 to March 2022, a total of 1010 HD sessions were conducted on 175 patients. 198 199 The average frequency of dialysis sessions was calculated at  $5.8 \pm 3.8$  per patient, ranging from one single session to a maximum of fifteen sessions with each session lasting an average 200 201 duration of approximately  $3.1 \pm 0.6$  hours. Patients underwent HD therapy thrice weekly using 202 catheters as the primary means for vascular access across all cases in this study. During these treatments, blood products were administered in approximately 9.8% or essentially, during 203 almost ten out all hundred HD procedures. UFH was administered for circuit anticoagulation 204 205 in 626 sessions, accounting for 62% of the total. The average dose given was 1 mL (5000 IU). Of these UFH sessions, infusion was stopped 60 minutes before discontinuation in 546 cases, 206 making up 87.2% of the total. The average pressure in the venous chamber was recorded as 207  $125 \pm 39.3$  mmHg, with the dialysis blood flow rate averaging  $227.2 \pm 22.8$  ml/min. 208

| Variables                            |          | mean ± SD        |
|--------------------------------------|----------|------------------|
| Total number of HD sessions (N=1010) |          | 5.8 ± 3.8        |
| HD duration (in hour)                |          | 3.1 ± 0.6        |
| Venous chamber pressure (mmHg)       |          | $125 \pm 39.3$   |
| Ultrafiltration volume (ml)          |          | $885 \pm 650.9$  |
| Blood flow rate (ml/min)             |          | $227.2 \pm 22.8$ |
| Dialysate flow rate (ml/min)         |          | $481 \pm 46.6$   |
| Total UFH dose (ml)*                 |          | $1 \pm 0.2$      |
|                                      | Category | n (%)            |
|                                      |          |                  |

#### 209 Table 4: Characteristics of HD sessions included in the study (N=1010)

UFH infusion stopped

| Before 30 minutes      | 70 (11.3)  |
|------------------------|------------|
| Before 60 minutes      | 546 (87.2) |
| Before 120 minutes     | 8 (1.3)    |
| At the end of dialysis | 1 (0.2)    |

210

#### 211 Anticoagulation-related complication and HD Outcome

Of the 175 patients, extracorporeal circuit clotting occurred in 34 patients in 39 (3.9%) sessions 212 and 27 patients in 29 (2.9%) experienced bleeding. HD circuit clotting resulted in the 213 discarding of the bloodline and early termination of dialysis in 17 sessions. Additionally, 214 nursing interventions, that is, the use of UFH and a normal saline flush, were required in 10 215 216 and 5 sessions, respectively, to prevent abrupt HD treatment interruptions due to circuit clotting. Some of the measures taken when bleeding occurred included holding UFH at the 217 time, and for the next session/s (n = 14 sessions), blood transfusion (n = 2 sessions), and 218 applying pressure at catheter insertion site in 6 sessions (Table 5). On the other hand, the 219 majority of AKI patients (44.6%) were discharged with improvement, while more than one-220 fourth (26.9%) of them died after undergoing HD (Figure 1). 221

- 222 Table 5: Anticoagulation related complication and HD outcome among AKI patients in
- the study.

| Variables                                   |                            | mean ± SD |
|---|----------------------------|-----------|
| Circuit clotting (34 patients, 19.4%)       |                            | 39 (3.9)  |
| Measures taken when circuit clotting occurs | Discard the blood line and | 17 (1.7)  |
|   | HD terminated early        |           |

| Blood transfusion during HD         |                           | 99 (9.8) |
|-------------------------------------|---------------------------|----------|
| Using UFH during HD                 |                           | 626 (62) |
|                                     | Additional UFH given      | 10(1)    |
|                                     | Continued HD by using     | 5 (0.5)  |
|                                     | normal saline flush       |          |
|                                     | Return the blood and HD   | 2 (0.2)  |
|                                     | terminated early          |          |
|                                     | Manipulate the access and | 3 (0.3)  |
|                                     | continued HD              |          |
|                                     | Use UFH intermittently    | 2 (0.2)  |
|                                     | for the next sessions     |          |
| Bleeding (27 patients, 15.4%)       |                           | 29 (2.9) |
|                                     | Bleeding from nose        | 15 (1.5) |
|                                     | Catheter site bleeding    | 6 (0.6)  |
|                                     | Vaginal bleeding          | 4 (0.4)  |
|                                     | Others**                  | 4 (0.4)  |
| Measures taken when bleeding occurs | Hold UFH at the time, and | 14 (1.4) |
|                                     | for the next session/s    |          |
|                                     | Blood transfused          | 2 (0.2)  |
|                                     | Applied pressure at       | 6 (0.6)  |
|                                     | catheter insertion site   |          |
|                                     | Use UFH intermittently    | 2 (0.2)  |
|                                     | for the next sessions     |          |
|                                     | Return the blood and HD   | 1 (0.1)  |
|                                     | terminated early          |          |

No measure taken 4(0.4)

224 \**1ml=5000 IU* 

\*\* bleeding form rectum, bloody vomiting, subcutaneous hematoma, bleeding form bullet
penetrating injury site

#### 227 Factors associated with anticoagulation related outcomes

To determine the predictors of anticoagulation-related outcomes during HD (clotting and bleeding risks), multinomial regression analysis was used. Based on the model comparing participants who had HD circuit clotting with those who did not have any clotting/bleeding, as the total number of HD sessions increased, the probability of circuit clotting increased (AOR=1.932, 95% CI, 1.227-3.043, p= 0.004). In contrast, a higher blood flow rate was associated with a lower HD circuit clotting risk (AOR=0.868, 95% CI, 0.812-0.928, p= 0.001).

On the other hand, bleeding was more likely to occur in participants who had longer 235 236 hospitalization and elevated serum creatinine at admission (AOR=1.247, 95% CI, 1.053-1.478, p= 0.010; AOR=1.886, 95% CI, 1.285-2.769, p= 0.001) respectively. While, the rate of 237 bleeding in patients who had no uremic signs and symptoms was lower (AOR=0.092, 95% CI, 238 0.009-0.955, p= 0.004) than those having it. Likewise, patients who did not receive 239 prophylactic or therapeutic anticoagulant and/or antiplatelet drug were less likely to develop 240 bleeding (AOR=0.017, 95% CI, 0.001-0.446, p= 0.014) compared to those taking these drugs 241 (Table 6). 242

#### Table 5: Multinomial regression of predictive factors associated with anticoagulation 243

#### related outcomes during HD 244

| Variables                   |                                  | Outcomes                         |         |
|-----------------------------|----------------------------------|----------------------------------|---------|
|                             | Clotting                         | Bleeding                         | P-value |
|                             | AOR (95% CI)                     | AOR (95% CI)                     |         |
| Total no of HD sessions     | 1.932 (1.227-3.043) <sup>a</sup> | 1.068 (0.713-1.601)              | 0.004*  |
| Blood flow rate (ml/min)    | 0.868 (0.812-0.928) <sup>a</sup> | 1.026 (0.974-1.081)              | <0.001* |
| Length of hospitalization   | 0.946 (0.843-1.06)               | 1.247 (1.053-1.478) <sup>a</sup> | 0.010*  |
| (days)                      |                                  |                                  |         |
| Serum creatinine (mg/dl) at | 0.911 (0.699-1.189)              | 1.886 (1.285-2.769) <sup>a</sup> | 0.001*  |
| admission                   |                                  |                                  |         |
| Uremic signs and symptoms   |                                  |                                  |         |
| Yes                         | 1                                | 1                                |         |
| No                          | 0.532 (0.079-3.57)               | 0.092 (0.009-0.955) <sup>a</sup> | 0.04*   |
| Using of anticoagulant      |                                  |                                  |         |
| and/or antiplatelet drug    |                                  |                                  |         |
| Yes                         | 1                                | 1                                |         |
| No                          | 1.156 (0.168-7.936)              | 0.017 (0.001-0.446) <sup>a</sup> | 0.014*  |
|                             |                                  |                                  |         |

Reference Variable: No clotting/bleeding 245

\*Variables that showed a significant association, P < 0.05246

<sup>*a*</sup>*Variable category with* P < 0.05247

## 248 **Discussion**

As the first prospective study in the Ethiopian context on anticoagulation among patients with AKI on HD, this study provides insight into extracorporeal circuit clotting or bleeding occurrences and the predictive factors associated with these complications. In this study, 1010 HD sessions performed on 175 patients were prospectively followed. Clotting and bleeding data are expressed as percentages of both participants and sessions. Circuit clotting occurred in 3.9% of HD sessions (19.4% patients), and bleeding in 2.9% sessions (15.4% patients).

A similar result was reported in the United States of America, that evaluated clotting of the HD 255 circuit in general care patients and critically ill patients. The overall rate of extracorporeal 256 circuit clotting was 5.2% in all sessions (12). Circuit clotting occurred in 2.4% of HD sessions 257 with heparin, according to a retrospective study comparing two intra-dialytic heparin protocols: 258 "routine heparin-use" during HD (routine heparin prime/bolus dose) and heparin-free HD 259 (saline prime, heparin avoidance). However, heparin-free HD is associated with a higher rate 260 261 of HD circuit clotting (9.1%) (13). In contrast, other studies reported a higher rate of circuit 262 clotting during HD. A study conducted in Brazil showed that filter clotting occurred in 19 patients (25.3%) and 29 sessions (14.9%) (19). This study evaluated and compared intra- and 263 264 post-dialysis complications in critically ill AKI patients undergoing extended daily dialysis sessions of different durations (6 versus 10 hours), which could explain the higher rate of HD 265 filter clotting events, and the fact that many critically ill patients develop hemostatic 266 abnormalities in addition to the longer dialysis duration. 267

Additionally, a retrospective cohort study conducted in Belgium found that circuit coagulation was reported in 17.5% of the sessions. This higher rate of clotting events could be attributed to the absence of systemic anticoagulation (20). Moreover, this study conducted a retrospective

analysis of HD sessions in intensive care unit patients, which could be an additional factor
contributing to clotting occurrences. Patients admitted to the intensive care unit and requiring
dialysis for AKI often present with a systemic inflammatory state (21), which is known to be
associated with the activation of coagulation pathways (22).

Lower clotting of the HD circuit incidence was reported in a retrospective study conducted in 275 the USA (1% of 400 HD treatments) (23). This may be attributed to the operational definition 276 277 of clotting used in this study. The researchers defined clotting as complete clotting that required replacement of the blood tubing and dialyzer to complete treatment. The higher blood flow rate 278  $(378 \pm 46 \text{ mL/min})$  and more aggressive normal saline flushing of the circuit employed in this 279 protocol could also explain the lower rate of clotting. Moreover, there might be underreporting 280 of clots due to the retrospective study design, in which existing data were extracted from chart 281 reviews. Another study from Spain found that 1.9% of patients developed clotting, which is 282 lower than our finding (19.4% of patients) with a higher mean blood pump flow ( $346 \pm 47$ 283 ml/min), given a higher risk of coagulation from a lower pump flow (17). 284

In the current study, 15.4 % of patients developed bleeding, and this finding was higher than a study conducted in Spain (4.4%) (17). This variation might be due to the difference in the study design and setting, even though the study reported that oral anticoagulants were administered to 18.4% of patients, which by itself is thought to increase the risk of bleeding. However, in a Spanish study, each patient was asked to report any bleeding or thrombotic complications that arose in the week prior to data collection.

In the present study, it was observed that anticoagulation was achieved with UFH or saline flushes of 30 to 50 ml administered every 30 min if UFH was contraindicated. There were three strategies regarding UFH order for HD in current study settings, and each patient was dialyzed using any of these anticoagulation methods. The first is the standard dosing regimen of UFH,

consisting of a bolus of 1250–2000 U, followed by a continuous infusion of 1000–1250 U/h.
The second was the minimal/half-dose method with a 625–1000 bolus dose and 500–625
infusion rate. Heparin-free dialysis was also the third method used in patients who were
actively bleeding or were at an increased risk of bleeding.

Due to its brief half-life and extensive medical usage over time, UFH has emerged as the predominant anticoagulant for HD (9). Nonetheless, the dosage administered shows significant divergence. This study reveals that the average total UFH dose throughout HD sessions was  $5000 \pm 1000$  units, with heparin infusion being discontinued one hour before dialysis completion in the majority (87.2%) of cases to reduce the potential for bleeding from the access site post needle withdrawal.

In the present study, extracorporeal circuit clotting was assessed by visual inspection and noted by nurses. It is characterized by extremely dark blood or black striations in the tube and a sudden rise in pressure readings. They only recorded clotting as being present or absent without grading it in line with several studies done elsewhere (13,17,19,24). In contrast, other studies have reported the degree of clotting by classifying it as mild/slight, moderate, and severe.

HD is often performed three times a week for three–four hours each session; however, the length of these sessions varies from patient to patient. One consequence of intradialysis, circuit clotting, includes treatment interruption and patient blood loss, which may exacerbate haemodynamic instability (19). In 1.7% of all sessions with clotting, dialysis was stopped early without the possibility of retransfusing blood from the extracorporeal circuit; hence, the bloodline was discarded. However, in 0.2% of the sessions, dialysis was terminated early by the return of blood.

According to a study from Belgium, clotting reduced the length of time spent receiving dialysis 317 in 15.2% of sessions, completely blocking the circuit, and preventing retransfusion in 4.2% of 318 sessions, which is greater than our findings (20). These variations may be due to differences in 319 dialysis protocols. In contrast to our study, the study combined a citrate-enriched dialysate with 320 a heparin-coated dialyzer with no systemic UFH. Similarly, a study conducted in the USA 321 comparing two intradialytic heparin protocols reported that in a heparin-free HD protocol, 322 323 circuit clotting resulted in a change of the extracorporeal circuit in 7.3% of sessions. However, this was required in only 0.8% of HD sessions with heparin, and early termination of HD 324 325 (1.6%) was similar to that in this study (13). Bleeding is another important intradialysis complication that might require adjusting the dose of UFH (1.6% of all sessions with bleeding) 326 or blood transfusion (0.2%). Another study revealed that patient weight, circuit clotting, and 327 bleeding of the vascular access after disconnection were the most frequently employed 328 techniques for changing the dosage (17). 329

Identifying predictors of anticoagulation-related outcomes during HD in patients with AKI is 330 important. Identifying and preventing patients at risk of such complications can increase 331 practitioner awareness of HD-related complications. Similar to other studies (12,13,20,23), the 332 blood flow rate showed a statistically significant association with the occurrence of circuit 333 334 clotting. In this study, lower delivered blood flow rates were associated with higher circuitclotting rates. Additionally, as the total number of HD sessions increased, the probability of 335 circuit clotting increased, unlike in a study conducted in Belgium (20). This difference could 336 be due to variations in their research methodology and the inclusion of study participants with 337 varying levels of clotting risk. Patients who did not receive prophylactic or therapeutic 338 anticoagulants and/or antiplatelet drugs were less likely to develop bleeding compared to those 339 340 taking these drugs. Similarly, a study from Spain found that bleeding complications were more

frequent in patients receiving oral anticoagulants (17). Consistent with previous studies, ageand sex were not associated with bleeding events (13,17).

However, there were some limitations to our study. Bleeding was reported only at the time of the dialysis session. Therefore, this may not provide a comprehensive picture of the bleeding risk associated with dialysis. Additionally, the study did not exclude patients with comorbidities (such as deep vein thrombosis, active malignancy, severe heart failure, or severe liver disease). These conditions can impact anticoagulation outcomes and may confound the interpretation of results.

## 349 **Conclusions**

In conclusion, clotting was observed in 19.4% of the participants in the study, while bleeding 350 was reported in 15.4% of them. These findings highlight the importance of thorough 351 monitoring due to the complications resulting in treatment interruptions and blood loss. The 352 study identified a significant association between circuit clotting and variables such as blood 353 flow rate and the frequency of HD sessions. Furthermore, it revealed a notable occurrence of 354 bleeding during HD, mainly manifesting as minor cases. Individuals who received prophylactic 355 or therapeutic anticoagulants and/or antiplatelet medications were more susceptible to bleeding 356 compared to those who did not undergo these treatments. 357

358

## 359 Abbreviations

AKI: Acute Kidney Injury; HD: Hemodialysis; SPHMMC: St. Paul's Hospital Millennium
 Medical College; TASH: Tikur Anbessa Specialized Hospital; UFH: Unfractionated heparin.

## 362 Acknowledgement

The authors thank the School of Pharmacy, College of Health Sciences, Addis Ababa University, and the nursing staff at TASH and SPHMMC dialysis clinics, who were very cooperative and helpful in providing constant assistance.

# **366** Availability of Data and Materials

All the data and materials used in this paper are available from the corresponding author uponreasonable request.

## 369 **Disclosure interest**

370 The authors declare that they have no conflicts of interest.

# **Funding details**

372 The authors received no specific funding for this study.

| 373 |  |  |  |
|-----|--|--|--|
| 374 |  |  |  |
| 375 |  |  |  |
| 376 |  |  |  |
| 377 |  |  |  |
| 378 |  |  |  |
| 379 |  |  |  |
| 380 |  |  |  |
| 381 |  |  |  |
| 382 |  |  |  |
| 383 |  |  |  |
|     |  |  |  |

## 384 **References**

- Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011;79(12):1361–9.
- Daugirdas JT, Blake PG, Ing TS. Handbook of dialysis: Fifth edition. Handbook of Dialysis: Fifth Edition. 2014. 1–900 p.
- Dirkes S, Wonnacott R. Continuous Renal Replacement Therapy and Anticoagulation:
   What Are the Options? Am Assoc Crit Nurses. 2016;36(2):1–12.
- Ross S. Anticoagulation in Intermittent Hemodialysis: Pathways, Protocols, and
   Pitfalls. Vet Clin North Am Small Anim Pract. 2011;41(1):163–75.
- Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int.
  2007;11(2):178–89.
- Mhatre V. Ho, Ji-Ann Lee and KCM. Use and Safety of Unfractionated Heparin for
  Anticoagulation During Maintenance Hemodialysis. Am J Kidney Dis. 2012;23(1):1–
  7.
- 399 7. Srisawat N, Lawsin L, Uchino S, Bellomo R, Kellum JA. Cost of acute renal
  400 replacement therapy in the intensive care unit: Results from The Beginning and Ending
  401 Supportive Therapy for the Kidney (BEST Kidney) Study. Crit Care. 2010;14(2):1–10.
- 402 8. Kessler M, Moureau F, Nguyen P. Anticoagulation in Chronic Hemodialysis: Progress
  403 Toward an Optimal Approach. Semin Dial. 2015;28(5):474–89.
- 404 9. Cronin RE, Reilly RF. Unfractionated Heparin for Hemodialysis: Still the Best Option.
  405 Semin Dial. 2010;23(5):510–5.
- 406 10. European Best Practice Guidelines Expert Group on Hemodialysis ERA. Section V.
   407 Chronic intermittent haemodialysis and prevention of clotting in the extracorporal
   408 system. Nephrol Dial Transpl. 2002;17:63–71.
- Royal Liverpool and Broadgreen University Hospitals NHS Trust. Protocol for
   anticoagulation of extracorporeal circuits during kidney replacement therapy or plasma
   exchange. 2015.
- 412 12. Safadi S, Albright RC, Dillon JJ, Williams AW, Alahdab F, Brown JK, et al.
  413 Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute
  414 Care Inpatient Practice. Kidney Int Reports [Internet]. 2017;2(4):695–704. Available
  415 from: http://dx.doi.org/10.1016/j.ekir.2017.03.003
- 416 13. Liang E. Outcomes Associated with a Heparin-Free Hemodialysis Protocol and
  417 Review of the Literature. J Clin Nephrol Ren Care. 2016;2(1):1–6.
- 418 14. Muleta MB, Abebe E, Tadesse M, Berhae T, Muhammed M, Woodside K, et al.
  419 Original Article Milestones of Renal Replacement Therapy in Ethiopia. Ethiop Med J.
  420 2020;Supplement(January):5–13.
- 421 15. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage

| 422<br>423               |     | associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20(4):872–81.  |
|--------------------------|-----|--|
| 424<br>425<br>426        | 16. | Krummel T, Scheidt E, Borni-duval C, Bazin D, Lefebvre F, Nguyen P, et al.<br>Haemodialysis in patients treated with oral anticoagulant : should we heparinize ?<br>2014;29(4):906–13.   |
| 427<br>428               | 17. | Herrero-Calvo JA, González-Parra E, Pérez-García R, Tornero-Molina F. Spanish study of anticoagulation in haemodialysis. Rev Nefrol. 2012;32(2):153–9.   |
| 429<br>430<br>431        | 18. | Shibiru T, Gudina EK, Habte B, Deribew A, Agonafer T. Survival patterns of patients on maintenance hemodialysis for end stage renal disease in Ethiopia : summary of 91 cases. BMC Nephrol. 2013;14(1–6).  |
| 432<br>433<br>434        | 19. | Albino BB, Balbi AL, Ponce D. Dialysis complications in AKI patients treated with extended daily dialysis: Is the duration of therapy important? Biomed Res Int. 2014;2014.  |
| 435<br>436<br>437<br>438 | 20. | François K, Wissing KM, Jacobs R, Boone D, Jacobs K, Tielemans C. Avoidance of systemic anticoagulation during intermittent haemodialysis with heparin-grafted polyacrilonitrile membrane and citrate-enriched dialysate: A retrospective cohort study. BMC Nephrol. 2014;15(1):1–7. |
| 439<br>440               | 21. | Aleksandrova I V., Reĭ SI, Pervakova EI. Acute renal failure in critically ill patients.<br>Anesteziol Reanimatol. 2007;294(4):72–6.   |
| 441<br>442               | 22. | Franchini M, Veneri D, Lippi G. Inflammation and hemostasis: A bidirectional interaction. Clin Lab. 2007;53(1–2):63–7.   |
| 443<br>444               | 23. | Sahota S, Rodby R. Inpatient hemodialysis without anticoagulation in adults. Clin Kidney J. 2014;7(6):1–5.   |
| 445<br>446               | 24. | Murea M, Russell GB, Daeihagh P, Saran AM, Pandya K, Cabrera M, et al. Efficacy and safety of low-dose heparin in hemodialysis. Hemodial Int. 2018;22(1):74–81.  |

# Figure 1: HD outcome among AKI patients in the study



